| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Leukotriene B4 12-hydroxydehydrogenase (LTB4DH) – Induces LTB4DH expression (synergistically with calycosin or formononetin) [3]
|
|---|---|
| ln Vitro |
COX-2 is inhibited by the antioxidant gallic acid[1]. Following an 18-hour gallic acid treatment, 26.4% of the neutrophils that required treatment—or 40.3% of the total—were still alive after treatment. Cumene cannot be broken down by gallic acid and myocyte lysis cannot occur [3].
- In HepG2 cells, gallic acid (8 μg/mL) alone did not induce LTB4DH mRNA expression; but in combination with Radix Astragali extracts or calycosin (10 μg/mL) or formononetin (10 μg/mL), it synergistically induced LTB4DH expression after 24 h treatment [3] - In human neutrophils, gallic acid (8 μg/mL) combined with calycosin (10 μg/mL) induced LTB4DH mRNA expression in a time-dependent manner (detectable after 6 h) [3] - In human neutrophils, gallic acid (8 μg/mL) alone showed weak LTB4DH induction; combination with calycosin (10 μg/mL) or formononetin (10 μg/mL) significantly increased LTB4DH mRNA expression (p < 0.001) [3] - Gallic acid (8 μg/mL) combined with calycosin (10 μg/mL) diminished LTB4 (100 nM)-induced neutrophil survival: after 18 h treatment, viable neutrophils decreased from 40.3% (LTB4 alone) to 27.7% (combination), comparable to untreated control (26.4%) [3] - Gallic acid (8 μg/mL) combined with calycosin (10 μg/mL) inhibited LTB4-induced neutrophil chemotaxis in a TransWell assay (pore size 8 μm) after 24 h pre-treatment; combination showed strongest inhibition against 10 nM and 100 nM LTB4 [3] |
| ln Vivo |
The gallic acid group's body weight (2.5±0.69 g, p=0.76) and food approval amount (2.6±0.08 g/day, p=0.69) differed substantially from the body weight (food approval amount: 2.41±0.14 g/day and body weight: 2.83±0.84 g/day). After two weeks of treatment, there was a considerable improvement in the gallic acid group's blood pressure tolerance. After two weeks of therapy, the gallic acid group's blood pressure tolerance was also significantly lowered, with tachycardia observed at 90 and 120 minutes (p<0.05). The group's serum triglyceride concentration was significantly lower in the gallic acid group (0.67±0.03 mM, p<0.05) than in the Manhattan group (1.08±0.20 mM). Gallic acid (3.01±0.18 mM) and Manhattan (3.19±0.27 mM). the overall depth enrichment of the group [2].
- In isoproterenol-induced mouse model of myocardial infarction (male C57BL/6 mice, 6-8 weeks, 20-22 g), gallic acid (8 mg/kg/day, i.p. for 3 days) alone failed to attenuate isoproterenol-induced myocytolysis (H&E staining). However, combination with calycosin (40 mg/kg/day, i.p.) synergistically preserved cardiac morphology [3] - Gallic acid alone (8 mg/kg/day, i.p.) showed inhibitory effect on isoproterenol-induced neutrophil infiltration (Ly6G immunohistochemistry), but combination with calycosin (40 mg/kg/day) synergistically reduced infiltration (p < 0.05) [3] - Gallic acid alone did not significantly reduce isoproterenol-induced increase in myeloperoxidase (MPO) activity; combination with calycosin significantly reduced MPO activity (p < 0.05) [3] - Gallic acid alone (8 mg/kg/day) effectively reduced isoproterenol-induced increase in malondialdehyde (MDA) levels (p < 0.05); combination with calycosin also showed significant reduction (p < 0.01) [3] |
| Cell Assay |
- HepG2 cells were seeded in 6-well plates overnight and treated with gallic acid (8 μg/mL) alone or in combination with herbal fractions, calycosin (10 μg/mL), or formononetin (10 μg/mL) for 24 h. Total RNA was extracted and RT-PCR was performed for LTB4DH mRNA detection [3]
- Human neutrophils were freshly isolated and treated with gallic acid (8 μg/mL) and calycosin (10 μg/mL) in combination for 0, 3, 6, 9, and 18 h. RT-PCR was used to detect LTB4DH mRNA expression [3] - Human neutrophils were treated with LTB4 (100 nM) alone or combined with gallic acid (8 μg/mL) and calycosin (10 μg/mL) for 3, 6, 9, and 18 h. Apoptosis was analyzed by Annexin V-FITC/PI staining and flow cytometry [3] - Human neutrophils were pre-treated with gallic acid (8 μg/mL) and calycosin (10 μg/mL) individually or in combination for 24 h. Cells were labeled with Calcein AM (5 μM) and chemotaxis was assayed using TransWell plates (8 μm pore) toward LTB4 (0, 10, 100 nM) for 3 h. Migrated cells were quantified by fluorescence (ex/em 485/530 nm) [3] |
| Animal Protocol |
- Male C57BL/6 mice (6-8 weeks, 20-22 g) were randomly divided into 5 groups (n=6): Control (saline + vehicle, i.p., 0.5 mL/day for 3 days); ISO group (saline i.p. day1, then isoproterenol 100 mg/kg/day s.c. day2-3); ISO+GA (gallic acid 8 mg/kg/day i.p. for 3 days + isoproterenol 100 mg/kg/day s.c. day2-3); ISO+CA (calycosin 40 mg/kg/day i.p. for 3 days + isoproterenol day2-3); ISO+CA+GA (calycosin 40 mg/kg/day + gallic acid 8 mg/kg/day i.p. for 3 days + isoproterenol day2-3). Isoproterenol dissolved in 0.9% saline; gallic acid dissolved in 5% ethanol in 0.9% saline. Isoproterenol injected 10 min after drug injection [3]
- Half of animals from each group were euthanized by pentobarbital (200 mg/kg, i.p.) and fixed with 4% paraformaldehyde. Heart tissues were paraffin-embedded, sectioned (5 μm), and stained with H&E for histopathology [3] - For immunohistochemistry, cardiac sections were boiled in citrate buffer (pH=6) for 15 min, blocked in 5% goat serum for 1 h, probed with anti-Ly6G primary antibody (1:50) at 4°C overnight, then incubated with FITC-conjugated secondary antibody (1:200) for 1.5 h at room temperature. Images acquired by laser scanning microscope [3] - Frozen hearts were homogenized in PBS (pH 6.0) with 0.5% hexadecyltrimethylammonium hydroxide, centrifuged at 12,000 rpm for 20 min at 4°C. Supernatants were used for MPO activity and MDA level assays. Protein concentration determined by Bio-Rad protein assay [3] |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Easily absorbed from the gastrointestinal tract. After administration to rabbits, most of it is excreted unchanged in the urine, but small amounts are also excreted as pyrogallic acid and 4-methoxy-3,5-dihydroxybenzoic acid. Metabolism/Metabolites Gallic acid…is methylated to 3,5-dihydroxy-4-methoxybenzoic acid by catechol-O-methyltransferase. This enzyme is located in the sol component and is present in the liver, kidneys, skin, blood cells, glandular tissue, and nerve fibers. It requires S-adenosylmethionine as a methyl donor, as well as Mg++ or other divalent ions. After administration to rabbits, most of it is excreted unchanged in the urine, but small amounts are also excreted as pyrogallic acid and 4-methoxy-3,5-dihydroxybenzoic acid. After metabolism by intestinal flora, gallic acid is decarboxylated to pyrogallic acid. Gallic acid is converted into gallic acid-β-D-glucuronide in rabbits. /Excerpt from table/ |
| Toxicity/Toxicokinetics |
Non-Human Toxicity Values
Rabbit oral LD50: 5.0 g/kg |
| References |
|
| Additional Infomation |
Gallic acid is an odorless white solid that sinks in water. (US Coast Guard, 1999)
Gallic acid is a trihydroxybenzoic acid, with hydroxyl groups located at positions 3, 4, and 5. It possesses astringent, cyclooxygenase 2 inhibitor, plant metabolite, antioxidant, antitumor agent, human xenobiotic metabolite, EC 1.13.11.33 (arachidonic acid 15-lipoxygenase) inhibitor, apoptosis inducer, and anti-aging effects. It is the conjugate acid of gallic esters. Gallic acid is a metabolite found or produced in Escherichia coli (K12 strain, MG1655 strain). Gallic acid has been reported in Polygonum cuspidatum, tea trees, and other organisms with relevant data. Gallic acid is a metabolite found or produced in Saccharomyces cerevisiae. A colorless or slightly yellow crystalline compound extracted from Gallus gallus domesticus. It is used in photography, pharmaceuticals, and as an analytical reagent. See also: Gallic acid monohydrate (active ingredient); Paeonia lactiflora root (partial); Whole plant of Porcine hepatitis (partial)... See more... Therapeutic Uses Veterinary Drug: Formerly used as an intestinal astringent. Veterinary Drug: Antidiarrheal drug - Gallic acid was previously isolated from Radix Paeoniae Rubra through a bioactivity-guided fractionation procedure [3] - Gallic acid alone does not induce LTB4DH expression; it requires combination with calycosin or formononetin for synergistic induction [3] - The combination of gallic acid and calycosin represents a novel “multidrugs on one target” strategy for treating neutrophil-mediated myocardial injury [3] |
| Molecular Formula |
C7H6O5
|
|---|---|
| Molecular Weight |
170.12
|
| Exact Mass |
170.021
|
| CAS # |
149-91-7
|
| Related CAS # |
Gallic acid hydrate;5995-86-8;Gallic acid-d2;294660-92-7
|
| PubChem CID |
370
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
501.1±50.0 °C at 760 mmHg
|
| Melting Point |
252 °C (dec.)(lit.)
|
| Flash Point |
271.0±26.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.730
|
| LogP |
0.91
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
169
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=C(C(=C1O)O)O)C(=O)O
|
| InChi Key |
LNTHITQWFMADLM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)
|
| Chemical Name |
3,4,5-trihydroxybenzoic acid
|
| Synonyms |
HSDB2117; HSDB 2117;
Gallic acid; 3,4,5-Trihydroxybenzoic acid; 149-91-7; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~587.82 mM)
H2O : ~8.33 mg/mL (~48.97 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8782 mL | 29.3910 mL | 58.7820 mL | |
| 5 mM | 1.1756 mL | 5.8782 mL | 11.7564 mL | |
| 10 mM | 0.5878 mL | 2.9391 mL | 5.8782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
